|
US5506231A
(en)
*
|
1989-03-31 |
1996-04-09 |
The Children's Medical Center Corporation |
Treatment of aids dementia, myelopathy and blindness
|
|
US5334618A
(en)
*
|
1991-04-04 |
1994-08-02 |
The Children's Medical Center Corporation |
Method of preventing NMDA receptor-mediated neuronal damage
|
|
US5614560A
(en)
*
|
1991-04-04 |
1997-03-25 |
Children's Medical Center Corporation |
Method of preventing NMDA receptor-mediated neuronal damage
|
|
US5455279A
(en)
*
|
1991-04-19 |
1995-10-03 |
The Children's Medical Center Corporation |
Regimen method of mediating neuronal damage using nitroglycerine
|
|
WO1992017168A1
(en)
*
|
1991-04-04 |
1992-10-15 |
The Children's Medical Center Corporation |
Method of preventing nmda receptor-mediated neuronal damage
|
|
DE4225730C2
(de)
*
|
1992-08-04 |
2003-04-30 |
Merz Pharma Gmbh & Co Kgaa |
Verfahren zur Herstellung von festen Arzneiformkörpern mit protrahierter 2-Stufen-Freisetzung
|
|
US5866585A
(en)
*
|
1997-05-22 |
1999-02-02 |
Synchroneuron, Llc |
Methods of treating tardive dyskinesia using NMDA receptor antagonists
|
|
US6057373A
(en)
*
|
1997-05-22 |
2000-05-02 |
Synchroneuron, Llc |
Methods of treating tardive dyskinesia and other movement disorders using NMDA receptor antagonists
|
|
US6294583B1
(en)
|
1998-01-13 |
2001-09-25 |
Synchroneuron, Llc |
Methods of treating tardive dyskinesia and other movement disorders
|
|
US5952389A
(en)
*
|
1998-01-13 |
1999-09-14 |
Synchroneuron |
Methods of treating tardive dyskinesia and other movement disorders
|
|
US6444702B1
(en)
|
2000-02-22 |
2002-09-03 |
Neuromolecular, Inc. |
Aminoadamantane derivatives as therapeutic agents
|
|
EP1427404A4
(en)
*
|
2001-08-20 |
2005-10-26 |
Maiken Nedergaard |
TREATMENT OF GLIAL TUMORS WITH GLUTAMATE ANTAGONISTS
|
|
EP1298581A1
(fr)
*
|
2001-09-27 |
2003-04-02 |
C.S.E.M. Centre Suisse D'electronique Et De Microtechnique Sa |
Procédé et dispositif pour calculer les valeurs des neurones d'un réseau neuronal
|
|
AU2003274353B2
(en)
|
2002-10-24 |
2007-04-05 |
Merz Pharma Gmbh & Co. Kgaa |
Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
|
|
UA80055C2
(en)
*
|
2003-05-27 |
2007-08-10 |
Forest Laboratories |
Combination of nmda-receptor antagonist and selective inhibitor of serotonin reuptake for a depression and other pscihiatric disorders treatment
|
|
CN1240668C
(zh)
*
|
2003-09-10 |
2006-02-08 |
上海医药工业研究院 |
一种新的盐酸美金刚制备方法
|
|
WO2005079779A1
(en)
*
|
2003-10-22 |
2005-09-01 |
Merz Pharma Gmbh & Co. Kgaa |
THE USE OF 1-AMINOCYCLOHEXANE DERIVATIVES TO MODIFY DEPOSITION OF FIBRILLOGENIC Aß PEPTIDES IN AMYLOIDOPATHIES
|
|
AR046314A1
(es)
|
2003-11-05 |
2005-11-30 |
Merz Pharma Gmbh & Co Kgaa |
Composiciones que comprenden ciclohexilaminas y aminoadamantanos
|
|
WO2005069742A2
(en)
*
|
2003-12-10 |
2005-08-04 |
Sun Pharmaceutical Industries Limited |
Crystal form ii of memantine hydrochloride
|
|
DK1703902T3
(da)
*
|
2004-01-05 |
2011-02-14 |
Merz Pharma Gmbh & Co Kgaa |
Memantin til behandling af mild til moderat Alzheimer's sygdom
|
|
CN100363329C
(zh)
*
|
2004-01-09 |
2008-01-23 |
南京大学 |
合成美金刚胺盐酸盐的方法
|
|
US7456224B2
(en)
*
|
2004-04-05 |
2008-11-25 |
Forest Laboratories Holdings, Ltd. |
Method for treating autism
|
|
US20060002999A1
(en)
*
|
2004-06-17 |
2006-01-05 |
Forest Laboratories, Inc. |
Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
|
|
EP1765287A2
(en)
|
2004-06-17 |
2007-03-28 |
Merz Pharma GmbH & Co. KGaA |
Immediate release formulations of memantine oral dosage forms
|
|
MXPA06014587A
(es)
*
|
2004-06-17 |
2007-04-27 |
Forest Laboratories |
Formulaciones de liberacion modificada de formulaciones de dosificacion oral de memantina.
|
|
TW200616608A
(en)
*
|
2004-07-09 |
2006-06-01 |
Forest Laboratories |
Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients
|
|
MX2007003267A
(es)
*
|
2004-09-23 |
2007-05-23 |
Merz Pharma Gmbh & Co Kgaa |
Memantina para el tratamiento de trastornos de conducta en la infancia.
|
|
US20060205822A1
(en)
*
|
2004-12-22 |
2006-09-14 |
Forest Laboratories, Inc. |
1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect
|
|
ATE444950T1
(de)
*
|
2005-01-11 |
2009-10-15 |
Teva Pharm Fine Chemicals Srl |
Verfahren zur herstellung von 1-amino-3,5- dimethyladamantan-hydrochlorid
|
|
ITMI20050833A1
(it)
*
|
2005-05-10 |
2006-11-11 |
A M S A S P A Anonima Materie Sintetiche Affini |
Nuovo procedimento per la sintesi di aminoadamantani
|
|
AU2006259619A1
(en)
*
|
2005-06-16 |
2006-12-28 |
Forest Laboratories, Inc. |
Modified and immediate release memantine bead formulation
|
|
BRPI0613943B1
(pt)
|
2005-07-27 |
2021-06-22 |
Otsuka America Pharmaceutical, Inc |
Composto, composição farmacêutica o compreendendo, usos de um composto e de uma composição farmacêutica, bem como composição neurobiologicamente ativa
|
|
US20070099947A1
(en)
*
|
2005-11-03 |
2007-05-03 |
Alkermes, Inc. |
Methods and compositions for the treatment of brain reward system disorders by combination therapy
|
|
ATE541827T1
(de)
*
|
2006-02-21 |
2012-02-15 |
Hexal Ag |
Verfahren zur herstellung von adamantanaminen
|
|
MX2007014913A
(es)
*
|
2006-03-27 |
2008-10-24 |
Teva Pharma |
Proceso para perparar clorhidrato de memantina sustancialmente libre de impurezas.
|
|
AR063680A1
(es)
|
2006-08-04 |
2009-02-11 |
Merz Pharma Gmbh & Co Kgaa |
Derivados de pirazolo[1, 5-a]pirimidina, metodos e intermediario para su preparacion, composiciones farmaceuticas que los comprenden y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades mediadas por la modulacion de mglur5.
|
|
EP1908748A1
(en)
*
|
2006-10-05 |
2008-04-09 |
Krka |
Process for the preparation of memantine and its hydrochloric acid salt form
|
|
WO2008063847A2
(en)
*
|
2006-11-03 |
2008-05-29 |
Forest Laboratories Holdings Limited |
Method for treating autism
|
|
AU2007333656A1
(en)
|
2006-12-19 |
2008-06-26 |
University Of Virginia Patent Foundation |
Combined effects of topiramate and ondansetron on alcohol consumption
|
|
EP2130828A4
(en)
|
2007-02-28 |
2010-12-29 |
Asahi Kasei Pharma Corp |
sulfonamide
|
|
US9133159B2
(en)
|
2007-06-06 |
2015-09-15 |
Neurovance, Inc. |
1-heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments
|
|
US20090069374A1
(en)
|
2007-06-06 |
2009-03-12 |
Phil Skolnick |
Novel 1-Heteroaryl-3-Azabicyclo[3.1.0]Hexanes, Methods For Their Preparation And Their Use As Medicaments
|
|
GB0713930D0
(en)
|
2007-07-18 |
2007-08-29 |
Generics Uk Ltd |
Novel assay methods
|
|
EP2085398A1
(en)
|
2008-02-01 |
2009-08-05 |
Merz Pharma GmbH & Co. KGaA |
Pyrazolopyrimidines, a process for their preparation and their use as medicine
|
|
EP2090576A1
(en)
|
2008-02-01 |
2009-08-19 |
Merz Pharma GmbH & Co.KGaA |
6-halo-pyrazolo[1,5-a]pyridines, a process for their preparation and their use as metabotropic glutamate receptor (mGluR) modulators
|
|
US20090247644A1
(en)
*
|
2008-03-28 |
2009-10-01 |
Forest Laboratories Holdings Limited |
Memantine formulations
|
|
US20110034565A1
(en)
|
2008-04-18 |
2011-02-10 |
University College Dublin, National University Of Ireland, Dublin |
Psycho-pharmaceuticals
|
|
EP2111858A1
(en)
|
2008-04-25 |
2009-10-28 |
EPFL Ecole Polytechnique Fédérale de Lausanne |
Novel treatment for alzheimer's disease
|
|
US20090275597A1
(en)
*
|
2008-05-02 |
2009-11-05 |
Forest Laboratories Holdings Limited |
Methods of treating cns disorders
|
|
EP2138173A1
(en)
|
2008-06-26 |
2009-12-30 |
Merz Pharma GmbH & Co.KGaA |
Pharmaceutical compositions comprising aminoadamantane derivatives
|
|
JP5195256B2
(ja)
*
|
2008-10-10 |
2013-05-08 |
東ソー株式会社 |
アミノアダマンタン誘導体の製造方法
|
|
HRP20090186A2
(hr)
|
2009-03-31 |
2010-10-31 |
Institut Ruđer Bošković |
Adamantanski bisureidni derivati, metoda priprave i primjena u detekciji aniona
|
|
WO2010112221A1
(en)
|
2009-04-03 |
2010-10-07 |
Synthon B.V. |
Pharmaceutical compositions comprising memantine
|
|
CN102070463A
(zh)
*
|
2009-06-11 |
2011-05-25 |
辽宁利锋科技开发有限公司 |
具有金刚烷结构药物美金刚胺及其衍生物和类似物抗肿瘤新适应症的应用
|
|
TW201116532A
(en)
|
2009-08-05 |
2011-05-16 |
Merz Pharma Gmbh & Co Kgaa |
Metabotropic glutamate receptor modulators
|
|
BR112012013487A2
(pt)
|
2009-12-02 |
2017-10-03 |
Adamas Pharmaceuticals Inc |
Composições de amantadina e métodos de uso
|
|
US20110251239A1
(en)
|
2010-04-07 |
2011-10-13 |
Eisai Inc. |
Combination therapy for the treatment of dementia
|
|
WO2012052451A1
(en)
|
2010-10-18 |
2012-04-26 |
Merz Pharma Gmbh & Co. Kgaa |
Metabotropic glutamate receptor modulators
|
|
EP2632897B1
(en)
|
2010-10-29 |
2014-10-01 |
Merz Pharma GmbH & Co. KGaA |
Indole derivatives and process for their preparation
|
|
WO2012068161A1
(en)
|
2010-11-15 |
2012-05-24 |
Agenebio, Inc. |
Pyridazine derivatives, compositions and methods for treating cognitive impairment
|
|
AR084516A1
(es)
|
2010-12-22 |
2013-05-22 |
Merz Pharma Gmbh & Co Kgaa |
Moduladores de receptores de glutamato metabotropicos
|
|
WO2012085167A1
(en)
|
2010-12-22 |
2012-06-28 |
Merz Pharma Gmbh & Co. Kgaa |
Metabotropic glutamate receptor modulators
|
|
CN102241678B
(zh)
|
2011-04-26 |
2014-10-29 |
辽宁利锋科技开发有限公司 |
含有脂环结构化合物的抗肿瘤作用与应用
|
|
WO2012152854A1
(en)
|
2011-05-12 |
2012-11-15 |
Merz Pharma Gmbh & Co. Kgaa |
Metabotropic glutamate receptor modulators
|
|
WO2012172093A1
(en)
|
2011-06-17 |
2012-12-20 |
Merz Pharma Gmbh & Co. Kgaa |
Dihydroindolizine derivate as metabotropic glutamate receptor modulators
|
|
US20140206740A1
(en)
|
2011-07-30 |
2014-07-24 |
Neurovance, Inc. |
Use Of (1R,5S)-(+)-(Napthalen-2-yl)-3-Azabicyclo[3.1.0]Hexane In The Treatment Of Conditions Affected By Monoamine Neurotransmitters
|
|
CN103288650B
(zh)
*
|
2012-02-28 |
2015-09-30 |
广州白云山制药股份有限公司广州白云山制药总厂 |
一种盐酸1-氨基-3,5-二甲基金刚烷的制备方法
|
|
EP2650284A1
(en)
|
2012-04-10 |
2013-10-16 |
Merz Pharma GmbH & Co. KGaA |
Heterocyclic derivatives as metabotropic glutamate receptor modulators
|
|
RU2488388C1
(ru)
|
2012-05-24 |
2013-07-27 |
Ооо "Валента Интеллект" |
Фармацевтическая композиция для профилактики и лечения психических, поведенческих, когнитивных расстройств
|
|
US10154971B2
(en)
|
2013-06-17 |
2018-12-18 |
Adamas Pharma, Llc |
Methods of administering amantadine
|
|
US9566264B2
(en)
|
2013-07-01 |
2017-02-14 |
Euthymics Bioscience, Inc. |
Combinations and methods
|
|
EP3083569B1
(en)
|
2013-12-20 |
2022-01-26 |
Agenebio, Inc. |
Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
|
|
JP6604957B2
(ja)
|
2014-02-04 |
2019-11-13 |
フォレスト・ラボラトリーズ・ホールディングス・リミテッド |
ドネペジル組成物及びアルツハイマー病を治療する方法
|
|
CA2990004C
(en)
|
2015-06-19 |
2024-04-23 |
Agenebio, Inc. |
Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
|
|
JP6354701B2
(ja)
*
|
2015-08-19 |
2018-07-11 |
大日本印刷株式会社 |
高純度メマンチン塩酸塩の製造法
|
|
WO2017223402A1
(en)
|
2016-06-23 |
2017-12-28 |
Corium International, Inc. |
Adhesive matrix with hydrophilic and hydrophobic domains and a therapeutic agent
|
|
WO2018022817A1
(en)
|
2016-07-27 |
2018-02-01 |
Corium International, Inc. |
Donepezil transdermal delivery system
|
|
AU2017302305A1
(en)
|
2016-07-27 |
2019-02-14 |
Corium, LLC. |
Transdermal delivery systems with pharmacokinetics bioequivalent to oral delivery
|
|
RU2764764C2
(ru)
|
2016-07-27 |
2022-01-21 |
Кориум Интернэшнл, Инк. |
Трансдермальные системы доставки мемантина
|
|
US20180170941A1
(en)
|
2016-12-19 |
2018-06-21 |
Agenebio, Inc. |
Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
|
|
US11505555B2
(en)
|
2016-12-19 |
2022-11-22 |
Agenebio, Inc. |
Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
|
|
US10369187B2
(en)
|
2017-02-09 |
2019-08-06 |
Vanderbilt University |
Peptide regulators of JNK family kinases
|
|
JP2019094304A
(ja)
*
|
2017-11-27 |
2019-06-20 |
学校法人順天堂 |
オートファジー誘導剤
|
|
CA3086163A1
(en)
|
2017-12-20 |
2019-06-27 |
Corium, Inc. |
Transdermal adhesive composition comprising a volatile liquid therapeutic agent having low melting point
|
|
EA202190076A1
(ru)
|
2018-06-19 |
2021-09-22 |
Эйджинбайо, Инк. |
Производные бензодиазепина, композиции и способы лечения когнитивных нарушений
|
|
US11639328B2
(en)
|
2020-05-19 |
2023-05-02 |
Shandong Holly Pharmaceutical Co., Ltd. |
Method for preparing amantadine
|
|
WO2024039886A1
(en)
|
2022-08-19 |
2024-02-22 |
Agenebio, Inc. |
Benzazepine derivatives, compositions, and methods for treating cognitive impairment
|
